The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) oncogene resulting from the t(2;5)(p23;q35) translocation is the causative agent of transformation of most anaplastic large cell lymphomas (ALCLs), as well as an increasing number of nonhematological disorders (Amin and Lai, 2007) . Dimerization by the NPM domain leads to autophosphorylation of the tyrosine kinase, in which constitutive activation is oncogenic. NPM-ALK mediates cellular transformation by taking control of signaling pathways involved in proliferation (for example, adaptors, mitogen-activated protein kinases (MAPKs), phospholipase Cg, protein tyrosine phosphatases (PTPs) or pp60 cÀsrc ), and in survival or antiapoptotic functions (phosphatidylinositol 3-kinase, PI3K/Akt pathway, or the Jak/ signal transducer and activator of transcription protein (STAT3-5) module) (Chiarle et al., 2008) . NPM-ALK( þ ) neoplasias are very aggressive and cells display a very distorted morphology with increased invasion capabilities resulting from modifications of the cytoskeleton dynamics through proteins such as p130Crk-associated substrate (p130Cas) and Rac1 guanosine triphosphate phosphatase (GTPase) (Ambrogio et al., 2005; Colomba et al., 2008) .
Reactive oxygen species (ROS) are established secondary messengers, which increase in many cancers and have been shown to promote many tumorigenic processes, including resistance to apoptosis, proliferation and metastasis (Perwez Hussain et al., 2003) . Recent observations have shown that ROS generation is an important step in signaling by receptor tyrosine kinases (RTKs), such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) receptors, where it helps to achieve optimal propagation of mitogenic and antiapoptotic signals. However, ROS production has never been investigated downstream of ALK. As signaling molecules, ROS were shown to oxidize critical targets for cell invasion, such as PTPs, MAPK, phosphate and tensin homolog (PTEN) or the Rac effector p21-activated kinase (PAK, proteins that are also affected by NPM-ALK (Honorat et al., 2006; Wu, 2006; Voena et al., 2007) . We therefore sought to analyse the levels of ROS in NPM-ALK( þ ) cells. Transfection of NPM-ALK in NIH-3T3 cells caused a four-fold increase in intracellular ROS levels, as measured using the ROS-sensitive fluorescent probe, C2938 (Figure 1a) . Similarly, NPM-ALK( þ ) ALCL cells (Karpas 299, SU-DH-L1 and the small cells variant Cost) had twice the levels of ROS as the NPM-ALK(À) cell line Fepd (Figure 1a) .
Besides mitochondrial respiratory pathways, ROS can be generated by nicotinamide adenine dinucleotide Figure 1 Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces lipoxygenase (LOX)-dependent reactive oxygen species (ROS) production, which in turn downregulates ALK activity. Both NIH-3T3 wild-type or transfected with NPM-ALK, and anaplastic large-cell lymphomas (ALCLs) were maintained in Dulbecco's modified Eagle's or Iscove's modified Dulbecco's media, respectively. Cultures were supplemented with 10% fetal calf serum (FCS), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 0.5 mg ml À1 geneticin (G418). (a) Control or NPM-ALK( þ ) NIH-3T3 and ALCL cells were incubated for 1 h with 0.5 mM of the redox-sensitive 6-carboxy-2 0 ,7 0 -dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester), C2938 (Invitrogen, Carlsbad, CA, USA), at 37 1C. Results were analysed by fluorescence-activated cell sorting (FACS) and expressed as fold increase over the level of control cells (control NIH-3T3 or Fepd). NPM-ALK expression was assessed by western blotting on whole-cell lysates probed with the ALK1 antibody (DakoCytomation, Glostrup, Denmark) tubulin was used as loading control (Sigma-Aldrich, St Louis, MO, USA). (b) Cost and Karpas 299 cells were treated with 10 mM nordihydroguaiaretic acid (NDGA), 10 mM N-acetyl cysteine (NAC) or 5 mM diphenyliodonium chloride (DPI) (Sigma-Aldrich) for 1 h and the level of ROS quantitated as above. Data from five experiments are expressed as mean±s.e.m *P o 0.05 (Student's t test) (c) Recombinant NPM-ALK was produced in vitro, from the pBSK-NPM-ALK plasmid, using the translation (TNT) kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. A total volume of 5 ml of the reaction was then pre-treated with 10 mM NDGA or 15 mM WHI-154 (Calbiochem, San Diego, CA, USA) and submitted to a kinase assay in 20 mM Hepes pH 7.4, 10 mM MnCl 2 , 10 mM NaF, 2 mM sodium orthovanadate (Na 3 VO 4 ), 30 mM ATP, 1 mM PMSF, 10 mg ml À1 leupeptin and 2 mg ml À1 aprotinin, for 15 min at room temperature. ALK activity was evaluated by western blotting with the anti-phosphoNPM-ALK(Y664) antibody (Cell Signaling Technologies, Beverly, MA, USA). ALK1 antibody was used to visualize total NPM-ALK. (d) Cost and Karpas 299 cells were incubated for 1 h with the indicated concentration of NDGA or NAC. Activation of NPM-ALK was assessed by western blotting using the antiphosphoNPM-ALK(Y664), ALK1 antibody was used as a loading control. Immunoreactive bands were detected by chemiluminescence using the SuperSignal detection system (Pierce Chemical Co., Rockford, IL, USA). phosphate (NADPH) oxidases and lipoxygenases (LOXs) during arachidonic-acid metabolism (D'Autre´aux and Toledano, 2007) . To assess the source of ROS in NPM-ALK( þ ) cells, ALCL cells were treated with the NADPH oxidase inhibitor diphenyliodonium chloride (DPI) or with nordihydroguaiaretic acid (NDGA), which inhibits the 5-, 12-and 15-LOX isoforms. Only NDGA treatment reduced ROS to similar levels as treatment with the anti-oxidant Nacetylcysteine (NAC, Figure 1b) . Treatment of the ALK(À) Fepd cells with NAC and NDGA also led to a decrease in ROS levels (Supplementary Figure 2a) . However, this decrease was lower than that for NPM-ALK( þ ) cells (25% for Fepd versus 60% for Cost and Karpas 299). These data suggest that ROS production was largely due to LOX activity in ALCLs.
We then proceeded to evaluate the effect of LOX inhibition by NDGA on NPM-ALK-dependent transformation and check whether it could impair ALK activation by measuring the NPM-ALK autophosphorylation on Y664 with specific antibodies. To ensure that the effects of NDGA were not due to non-specific direct inhibition of ALK activity, we first carried out an in vitro kinase assay. We found that NDGA did not cause any modification in Y664 phosphorylation of recombinant NPM-ALK, whereas the ALK inhibitor WHI-154 significantly reduced the phosphorylation ( Figure 1c ). By contrast, treatment of cells with NDGA resulted in a dose-dependent reduction of ALK phosphorylation in both Cost and Karpas 299 cells ( Figure 1d ). The inhibition of ALK auto-phosphorylation was likely because of ROS themselves, as similar effects were seen after NAC treatment ( Figure 1d ). Accordingly, treatment of Karpas 299 with hydrogen peroxide (H 2 O 2 ) resulted in an increase in NPM-ALK Y664 phosphorylation, reinforcing the idea that ROS modulate ALK activity (Figures 2a and b) . Among ROS targets, PTPs are redox-sensitive proteins because of the cysteine of their catalytic domain. PTPs such as PTP1B, low molecular weight-PTP (LMW-PTP) and the SH2-containing PTPs, SHP-1 and SHP-2, which are known regulators of NPM-ALK, were shown to be highly sensitive to ROS (Wu, 2006) . When we treated Karpas 299 cells with the PTP inhibitor sodium orthovanadate (Na 3 VO 4 ), an increase in Y664 phosphorylation was observed (Figure 2a) . The same pattern of NPM-ALK phosphorylation was seen in Cost cells (data not shown). The addition of NDGA or NAC together with sodium orthovanadate did not induce any significant modification of NPM-ALK phosphorylation, as shown in Figure 2b (compare lanes 3, 4 and 6). Examination of overall tyrosine phosphorylation in total lysates of cells treated by NDGA or NAC showed a strong decrease, whereas treatment with either orthovanadate or H 2 O 2 had the opposite effect, suggesting again that tyrosine phosphatases could be responsible for the effect observed on NPM-ALK (Figure 2c ). Together these data suggest a model whereby NPM-ALK activates LOX proteins, which produce ROS that might inactivate PTPs, resulting in a shift of equilibrium of tyrosine phosphorylation in favor of tyrosine kinases, thus reinforcing phosphorylation and activation of the oncogene.
In agreement with this theory, several signaling pathways shown to be important for NPM-ALKinduced transformation were downregulated on NDGA treatment (Figure 2d) . NDGA abolished the phosphorylation of Akt, STAT3 and ERK1/2, proteins known to trigger the antiapoptotic and pro-mitogenic effects of NPM-ALK. Interestingly, the MAPK p38 was activated by NDGA. There are conflicting reports in the literature as to whether 5-LOX, one of the LOX family members often found associated with cancers, regulates or is regulated by p38 (Radmark et al., 2007) . Differences seem to be due to cell types, with p38 and ERK being activators of 5-LOX mostly in neutrophils (Flamand et al., 2002) . In ALCLs, p38 activation seemed to be a consequence of LOX/NPM-ALK inhibition, as we found that the same p38 activation could be observed on NPM-ALK inhibition by other means, such as WHI-154 treatment (not shown).
To evaluate the functional effect of LOX in NPM-ALK-dependent transformation, the effect of NDGA on proliferation and survival of ALCLs cells was tested. NDGA completely inhibited proliferation of both Cost and Karpas 299 cells (Figure 3a) . In addition, apoptosis, measured by monitoring the cleavage of caspase 3, was engaged after 8 h of NDGA treatment to an extent that was comparable to direct inhibition of ALK activity by WHI-154 (Figure 3b) .
Interestingly, the use of a LOX inhibitor specific for 5-LOX, N-(3-phenoxycinnamyl)-acetohydroxamic acid (BW A4C), also induced apoptosis (Figure 3b ). Among the LOX family, the 5-LOX isoform has been shown to be involved in tumorigenesis, as its inhibition blocks proliferation of a wide variety of tumoral cells, including lymphoid and myeloid cancer cells (Pidgeon et al., 2007) . We found that NPM-ALK( þ ) ALCLs overexpressed 5-LOX (Figure 4a ), as already shown for other cancers (Pidgeon et al., 2007; Radmark et al., 2007) . The NPM-ALK-dependent increase in 5-LOX required ALK activity in lymphoid cells (Supplementary Figure 1a) . Indeed, treatment of Cost and Karpas 299 cells with WHI-154 dramatically decreased its expression, whereas the transfection of NPM-ALK into the NIH-3T3 fibroblasts was without effect, suggesting that 5-LOX levels downstream of NPM-ALK are regulated through a lymphoid lineage-specific mechanism (Figure 4a and Supplementary Figure 1a) . As NDGA also inhibits 12-and 15-LOX, we evaluated their potential expression by reverse transcription-polymerase chain reaction (RT-PCR) (Supplementary Table 1 ). Figure 4a and Supplementary Figure 1b Figure 1b) , suggesting that 5-LOX was the predominant isoform in the NPM-ALK( þ ) cells tested, and therefore the most likely target of NDGA treatment. Phosphorylation of Ser 523 of 5-LOX by protein kinase A (PKA) suppresses its activity, whereas dephosphorylation leads to activation and nuclear translocation of the enzyme (Radmark et al., 2007) . Accordingly, we observed a robust phosphorylation of Ser 523 in NPM-ALK(À) cells, that disappeared on expression of the oncogene (Figure 4a ). Moreover, nuclear translocation was observed in NPM-ALK( þ ) NIH-3T3 cells, confirming the regulation of 5-LOX activity by the oncogene (Figure 4b ). To further clarify the involvement of 5-LOX in the inhibition of NPM-ALK observed on NDGA treatment, we took an advantage of the 5-LOXspecific inhibitor, BW A4C (Tateson et al., 1988) . As observed with NDGA, incubation of ALCL cells with BW A4C also inhibited proliferation and ALK activity (Figures 4c and d) , apart from inducing apoptosis (Figure 3b) , strongly suggesting that 5-LOX plays an Lysates were analysed by western blotting using anti-phosphoAkt(S473), anti-AKT anti-phosphosignal transducer and activator of transcription factor 3 (STAT3)(Y705), anti-STAT3, anti-phospho-p38, anti-p38 and anti-extracellular signal-regulated kinase (ERK1/2) from Cell Signaling Technologies. Anti-phosphoERK1/2 were from SigmaAldrich.
ROS regulate NPM-ALK in ALCLs K Thornber et al important role in the effects of NDGA in NPM-ALK( þ ) cells. As already mentioned, Figure 4a and Supplementary  Figure 1b showed that Fepd expresses the three LOX family members inhibited by NDGA (5-, 12-and 15-LOX). However, when treated with NDGA, Fepd cells responded by decreasing their proliferation rate, but they did not engage apoptosis as shown by the lack of cleavage of caspase 3 (Supplementary Figures 2b and c) . This observation is in agreement with the levels of ROS being partially controlled by LOX family members in Fepd, but the overall effects of NDGA on those cells indicated that LOX might not be a major player in the oncogenicity of NPM-ALK(À) cell lines. Moreover, in agreement with 5-LOX being poorly expressed and inactive in Fepd, BW A4C had no effect on both proliferation and apoptosis (Supplementary Figures 2b  and c) .
The role of 5-and 12-LOX is fairly clear and procarcinogenic in the cell types studied (Fu¨rstenberger et al., 2006; Pidgeon et al., 2007) . In the field of hematological malignancies, the general interest for ROS and their metabolizing enzymes has recently been increasing. A recent report focusing on the LOX proteins inhibited by NDGA (5-, 12-and 15-LOX) demonstrated that 5-LOX was the most abundant isoform in leukemic blasts from acute myeloid and lymphoblastic leukemia, but no data gave any insight into its mechanism of action (Vincent et al., 2008) . A second paper demonstrated that 15-LOX was strongly expressed in Hodgkin Reed-Sternberg cells and pointed to the importance of LOX as potential therapeutic targets in malignant hemopathies. In this same study, the authors confirmed the absence of 15-LOX mRNA in several non-Hodgkin's lymphomas, but the role of ROS or LOX enzymes in ALCLs has so far never been investigated (Claesson et al., 2008) .
Our data demonstrate that the NPM-ALK chimera enhances its oncogenic properties by inducing ROS production through the LOX pathway. Work is now needed to clearly identify the targets of ROS produced downstream of NPM-ALK. However, understanding this process is made difficult by the fact that any LOX inhibitor or ROS scavenger will lead to inactivation of the oncogene. Interestingly, LOX activation generates ROS during the production of leukotrienes (LTs), which are important modulators of inflammation and immunity. There is now a clear link between inflammation and cancer, although the finer details of this interplay remain to be established. For example, it has been shown that LTB4, the major product of 5-LOX, is capable of recruiting and enhancing the activity of potential anti-tumor effector immune cells at the site of tumor development. However, other studies suggest that LOX products may prevent the anti-tumor immune response and thereby actively enhance tolerance to tumors (Pidgeon et al., 2007) . Future studies will define which bioactive LOX products affect the responses of the immune system into elimination or tolerance of tumors. It seems that this will depend on the type of tumor and/or on the microenvironment, which could allow either stimulation of growth and angiogenesis or efficient recruitment and activation of cells of the innate or adaptive immune system to detect and eliminate the tumor.
There is a significant number of compounds that target LOX enzymes. Some of them are natural products, such as resveratrol (from hellebore roots), which was used in pre-clinical and clinical trials with encouraging results (Aggarwal et al., 2004; Wu and Hua, 2007) . Pharmacological studies with LOX inhibitors in cancers are difficult to interpret, as there are few isotype-specific inhibitors. However, one proposed 5-LOX-selective inhibitor, used in asthma therapy, Zileuton, has proven useful in blocking several types of cancer in animal models, often in combination with another target, such as cyclooxygenase-2 (COX-2), as shown for colon cancer (Pidgeon et al., 2007) . The BCR-ABL chimeric oncogene also induces free radical production during its oncogenic process. Importantly, BCR-ABL induces self-mutagenesis through ROS production, leading to Imatinib resistance and relapses in some cases of acute myeloid leukemia, highlighting the potential of ROS as co-therapeutic targets (Koptyra et al., 2006) . Unraveling new therapeutic avenues involving specific targets is one of the most important aims in the treatment of ALCLs, for which the therapeutic option still relies on heavy ROS regulate NPM-ALK in ALCLs K Thornber et al polychemotherapies that lead to relapses in 30% of cases. As the ROS/LOX pathway appears central to NPM-ALK activity, it might represent an exciting new route to explore.
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